Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies

Trial Profile

CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anti CD4 CAR T cell therapy-iCell Gene Therapeutics (Primary)
  • Indications Peripheral T-cell lymphoma; Sezary syndrome
  • Focus Adverse reactions; First in man
  • Sponsors iCell Gene Therapeutics
  • Most Recent Events

    • 18 Nov 2019 New source identified and integrated: ClinicalTrials.gov: US National Institutes of Health (NCT04162340).
    • 14 Nov 2019 According to an iCell Gene Therapeutics media release, data from this study will be presented at the 61st American Society of Hematology (ASH) Annual Meeting to be held December 7-10, 2019 in Orlando, Florida.
    • 06 Nov 2019 Results released in the 61st Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top